IDT Australia (IDT.AX) Stock Price
IDT Australia Price
Revenue at IDT Australia has contracted by 1.3% per year over the past 19 years to 20.36 M AUD. Earnings per share have declined at 16.4% per year over the last 14 years. For IDT Australia, the net margin of -13.3% is down versus -9.6% a few years ago. At today's price the dividend yield works out to roughly 33.83%. The dividend has grown at 115.4% per year over the past 3 years.
IDT Australia stock price
IDT Australia business model & stock analysis
Frequently asked questions about IDT Australia
IDT Australia Ltd operates as a pharmaceutical manufacturing and distribution company. The company's business model focuses on developing, manufacturing, and marketing a diverse range of pharmaceutical products. IDT Australia Ltd specializes in research-based, innovative medicines and aims to provide high-quality and cost-effective healthcare solutions. With its state-of-the-art manufacturing facilities, the company offers contract manufacturing services to various global pharmaceutical companies. IDT Australia Ltd's business model revolves around delivering safe, efficacious, and reliable pharmaceuticals, ensuring the highest standards of quality and compliance. The company strives to be a trusted partner for pharmaceutical development and production, catering to the evolving needs of the healthcare industry.
IDT Australia Ltd is primarily active in the pharmaceutical industry.
The main competitors of IDT Australia Ltd in the market include pharmaceutical companies like Mayne Pharma Group Limited, Sigma Healthcare Limited, and Australian Pharmaceutical Industries Limited. These companies are also involved in the manufacturing and distribution of pharmaceutical products, making them direct competitors to IDT Australia Ltd.
IDT Australia Ltd is an Australian pharmaceutical company with a rich history and background. Established in 1975, IDT Australia has evolved into a prominent player in the pharmaceutical industry. The company specializes in the development, manufacturing, and marketing of active pharmaceutical ingredients (APIs), finished dose pharmaceuticals, and consumer healthcare products. With its state-of-the-art facilities and dedicated team of experts, IDT Australia has gained a reputation for delivering high-quality and innovative solutions. The company focuses on providing contract manufacturing and development services to both domestic and international customers. IDT Australia's commitment to excellence and its strong presence in the market make it a trusted name in the pharmaceutical sector.
IDT Australia Ltd has achieved several significant milestones in its history. One notable milestone is the acquisition of the HealthPro brand in 2010, which expanded their presence in the global pharmaceutical market. Additionally, the company received its Therapeutic Goods Administration (TGA) license in 2012, allowing them to manufacture and supply quality pharmaceutical products. Moreover, IDT Australia Ltd successfully obtained the Schedule 8 license in 2017, enabling them to manufacture and supply controlled substances. These milestones illustrate the company's commitment to growth and its ability to navigate regulatory requirements. IDT Australia Ltd continues to strive for excellence in the pharmaceutical industry.
IDT Australia Ltd is primarily present in Australia and New Zealand.
IDT Australia Ltd represents a strong commitment to innovation, quality, and customer satisfaction. The company values include integrity, transparency, and a focus on long-term sustainable growth. IDT Australia Ltd is dedicated to providing high-quality solutions and services in the pharmaceutical industry. Their corporate philosophy emphasizes collaboration, efficiency, and continuous improvement. With a dedicated team of professionals, IDT Australia Ltd aims to deliver value to its stakeholders through responsible and ethical practices. Overall, IDT Australia Ltd strives to be a trusted and reliable partner, offering cutting-edge solutions and contributing to the advancement of healthcare globally.
7 analysts currently rate the IDT Australia stock: 0 recommend buying, 3 holding and 4 selling.
Converted at the current exchange rate, the IDT Australia share trades at 0.02 EUR (0.04 AUD).
The IDT Australia share (IDT.AX) is listed on 1 stock exchanges, including: ASX (IDT.AX).
IDT Australia Ltd is a leading company in the production and distribution of high-quality pharmaceutical products, particularly in the development and production of high-quality active ingredients and intermediates for the synthesis of drugs. The company also offers its expertise in research and development as well as sales and marketing. The company is divided into several business areas, including the production of APIs (Active Pharmaceutical Ingredients), intermediates, and fine chemicals. The company is also involved in the development of synthesis routes and process development. IDT Australia Ltd has extensive expertise in the production of active ingredients and pharmaceuticals. The company's products are used in various areas such as human and veterinary medicine, agrochemistry, and the chemical industry. The APIs division includes a wide range of products, including analgesics, cardiology, antihypertensives, anti-infectives, antidiabetics, rheumatology, and dermatology. The company has expanded its product range to include new and innovative products to meet the increasing demand of its customers. IDT Australia Ltd prides itself on offering its customers high-quality products that meet the strict regulations of the FDA and international standards. The intermediates division is also important to the company's business model. IDT Australia Ltd produces intermediates for a variety of drug classes, including cancer drugs, infectious diseases, autoimmune diseases, and metabolic disorders. The company is able to provide its customers with tailor-made intermediates to meet their requirements and specific needs. Another important aspect of IDT Australia Ltd's business model is research and development. The company has extensive expertise and experience in the synthesis of active ingredients and pharmaceuticals. IDT Australia Ltd invests continuously in research and development to be able to offer its customers innovative products. The company is proud to be able to provide its customers with customized solutions and assistance in the implementation of development processes. In the area of sales and marketing, IDT Australia Ltd works closely with its customers from the pharmaceutical and chemical industries to offer them a wide range of services. The company provides its customers with technical support in the implementation of development processes and in the analysis of quality issues, as well as an efficient supply chain. In summary, IDT Australia Ltd is a renowned company specializing in the production of active ingredients and pharmaceuticals, intermediates, and fine chemicals. The company takes pride in offering its customers a wide range of products and utilizing the experience and expertise of its employees in the areas of research and development, process development, sales, and marketing. With its quality products and comprehensive services, IDT Australia Ltd is able to meet the needs of its customers and be a reliable partner in a competitive market.
The revenue of IDT Australia is 20.36 M AUD. This figure is based on current financial data and reflects the company's business performance.
The profit of IDT Australia is -2.72 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of IDT Australia is currently -6.27. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the IDT Australia stock.
The price-to-sales ratio (P/S) of IDT Australia is currently 0.84. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the IDT Australia stock.
The Eulerpool Quality Score for IDT Australia is 3/10.
The ISIN of IDT Australia is AU000000IDT0. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of IDT Australia is 502203. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of IDT Australia is IDT.AX. The ticker symbol is used to trade IDT Australia shares on the stock exchange.
IDT Australia stock
IDT Australia Peer Group
IDT Australia Ticker
IDT Australia FIGI
All fundamentals and in-depth analysis of IDT Australia
Our stock analysis for IDT Australia stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IDT Australia. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.